Skip to main content

menu
menu
person
Search

Interventional Cardiology

Medical & Preventive Cardiology

Lipidology & Atherosclerosis Prevention

CV RISK/DIABETES

A MULTI-SPECIALTY PERSPECTIVE

close

person

Home
Specialties
Submit A Question

J. Wouter Jukema, MD, PhD, FESC, FACC MC

J. Wouter Jukema, MD, PhD, FESC, FACC MC

Professor of Cardiology
Netherlands Heart Foundation
Chairman, Leiden Vascular Medicine
Leiden University Medical Center (LUMC)
Leiden, Netherlands

Related Videos

In light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study?

In light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study?

J. Wouter Jukema, MD, PhD, FESC, FACC MC

Since both PCSK9 outcome trials demonstrated impressive safety when LDL-C levels are lowered into ranges much lower than 70 mg/dL, what should be the approach of the interventional and medical cardiologist to achieving LDL-C levels in this range?

Since both PCSK9 outcome trials demonstrated impressive safety when LDL-C levels are lowered into ranges much lower than 70 mg/dL, what should be the approach of the interventional and medical cardiologist to achieving LDL-C levels in this range?

J. Wouter Jukema, MD, PhD, FESC, FACC MC

As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population?

As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population?

J. Wouter Jukema, MD, PhD, FESC, FACC MC

What has been your experience with respect to patient satisfaction, discontinuation rates and toleration of this injection-based approach to LDL-C management?

What has been your experience with respect to patient satisfaction, discontinuation rates and toleration of this injection-based approach to LDL-C management?

J. Wouter Jukema, MD, PhD, FESC, FACC MC

Although the AHA Guidelines emphasize CV risk and mortality reductions with statins, ODYSSEY Outcomes provides comparable evidence for alirocumab. How compelling is the evidence for PCSK9 inhibition as a mediator of CV risk and mortality reduction?

Although the AHA Guidelines emphasize CV risk and mortality reductions with statins, ODYSSEY Outcomes provides comparable evidence for alirocumab. How compelling is the evidence for PCSK9 inhibition as a mediator of CV risk and mortality reduction?

J. Wouter Jukema, MD, PhD, FESC, FACC MC

Disclaimer:
Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Clinical Webcasts®

Powered by BROADCASTMED